Efficiency of Donepezil in Elderly Patients for Prevention of POCD Dysfunction
Efficiency of Donepezil in Elderly Patients Undergoing Orthopedic Surgery Due to Underlying Postoperative Cognitive Dysfunction, a Multicenter Randomized Controlled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Diansan Su, M.D., Ph.D.
- Phone Number: +8618616514088
- Email: diansansu@yahoo.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200127
- Recruiting
- Renji Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Elder than 60 years old
- Speak Chinese Mandarin
- Scheduled to undergo hip or knee replacement surgery and lumbar spine surgery
- The operation time is more than 2 hours.
- Signed the informed consent
- American Society of Anesthesiologists (ASA) classification I-II
Exclusion Criteria:
- Existing cerebral disease, or have a history of neurological and psychiatric diseases including Alzheimer Disease, stroke, epilepsy and psychosis
- Existing cognitive impairment as evidenced by Mini-Mental State Examination scores below 24
- Several audition or vision disorder
- Patients with tumors or infections
- Unwillingness to comply with the protocol or procedures
- Can not communicate normally in Mandarin Chinese
- Existing bradycardiac arrhythmia (Heart rate <60 bpm for any reasons)
- Existing gastrointestinal ulcer
- Existing urinary incontinence
- Existing asthma or chronic obstructive pulmonary disease
- Postoperative admission to ICU
- Allergic to donepezil
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Donepezil
|
Donepezil a cholinesterase inhibitor, 5mg(1 pill)/ day for 7 days Po, was administrated from the day before surgery.
|
|
PLACEBO_COMPARATOR: Control
|
Placebo, 1 pill/ day for 7 days Po, was administrated from the day before surgery.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The incidence of POCD after the surgery.
Time Frame: up to 7 days
|
up to 7 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The incidence of postoperative delirium after surgery.
Time Frame: 1 to 7 days after surgery
|
1 to 7 days after surgery
|
|
POCD incidence one month, six months and one year after surgery.
Time Frame: one month, six months and one year after surgery
|
one month, six months and one year after surgery
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Diansan Su, Department of Anesthesiology Renji Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- DNPQ20200523
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Total Knee Arthroplasty
-
NCT07584915Enrolling by invitationTotal Knee Arthroplasty | Total Knee Arthroplasty Recovery
-
NCT05314491RecruitingTotal Knee Arthroplasty | Revision Total Knee Arthroplasty
-
NCT01576263CompletedTotal Knee Arthroplasty | Total Hip Arthroplasty
-
NCT07067060Not yet recruitingKnee Arthroplasty | Total Knee Arthroplasty | Unicompartmental Knee Arthroplasty
-
NCT03443284TerminatedTotal Knee Arthroplasty; Total Hip Arthroplasty
-
NCT03386786TerminatedTotal Knee Arthroplasty; Total Hip Arthroplasty
-
NCT04090125CompletedKnee Arthroplasty, Total | Knee Replacement, Total
-
NCT07199478CompletedTotal Knee Arthroplasty | Total Hip Arthroplasty | ERAS
-
NCT03876431CompletedTotal Knee Arthroplasty | Total Knee Replacement
-
NCT05434767CompletedTotal Knee Arthroplasty | Total Knee Replacement
Clinical Trials on Placebo
-
NCT03827590UnknownAcute Bronchitis | Acute Upper Respiratory Tract Infection
-
NCT02177513Completed
-
NCT02935712CompletedMale Subjects With Type II Diabetes (T2DM)
-
NCT06767540Not yet recruiting
-
NCT03198624CompletedPharmacokinetics | Safety Issues
-
NCT02982187CompletedPulmonary Disease, Chronic Obstructive
-
NCT04693039Completed
-
NCT01610388Completed
-
NCT04388215UnknownHypertension | Dyslipidemias